Personalis, Inc. (NASDAQ: PSNL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Personalis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.80, Personalis, Inc. trades at 19.9x sales and 7.5x book value. Over the last twelve months it generated about $81M of revenue and a net loss of $127M. It runs a gross margin of 16.7%, an operating margin of -156.7% and a net margin of -147.7%. It shows return on equity of -49.5%, return on invested capital of -50.6% and a free cash flow yield of -6.7%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 4.53. Over the past 52 weeks the share price ranged from $4.96 to $18.89, with a beta of 2.36.
Personalis, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 8 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.